Deinove Partners with Toulouse White Biotechnology to Optimize Deinococcus Production

Regulatory News:

DEINOVE (Paris:ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, announced a technology collaboration with Toulouse White Biotechnology (TWB), a pre-industrial demonstrator in industrial biotechnology based on renewable carbon.

The project, conducted in collaboration with the MetaToul* platform (INSA-LISBP Toulouse and MetaboHUB national infrastructure) headed by Prof. Jean-Charles Portais, aims to map the metabolic fluxes of the Deinococcus chassis, i.e. to create an inventory of all the potentialities of the microorganism in the production of molecules of interest. This mapping, both quantitative and qualitative, will serve as reference to identify and optimize all the metabolic pathways of the Deinococcus model to rapidly reach the target yield and productivity of industrial processes developed by DEINOVE. DEINOVE bases its development on cutting edge technological platforms and this project aims to further streamline its metabolic engineering projects and accelerate the industrial programs underway.

"This partnership will reinforce the unique expertise that we have built around Deinococcus. We will benefit from the excellence of TWB to increase the performance of our strain with a clear goal: moving towards the overproduction of a given compound. Our bacterium has major advantages as a bioindustrial chassis and our goal is to further enhance its fermentation performance to achieve commercial production processes as quickly as possible. This collaboration will make a major contribution," said Emmanuel PETIOT, CEO of DEINOVE.

"Based on both internal resources and MetaToul's expertise, TWB was rapidly able to propose DEINOVE a comprehensive and ambitious collaborative project. DEINOVE, TWB partner since its inception, launched the project on 21 April in Toulouse. Everything is in place for the work to succeed on time and generate results that contribute to the success of DEINOVE's industrial development," said David GUERRAND, in charge of Industry Partnerships at TWB.

About TWB

Toulouse White Biotechnology (TWB) is a preindustrial demonstrator whose goal is to speed up the development of industrial biotechnologies by facilitating exchanges between public research and industry. Its vocation is to contribute to the expansion of a bioeconomy based on the use of renewable carbon in various fields (chemistry- biochemistry, materials, energy, etc.). Various kinds of collaborative research and development projects are proposed, as well as personalized services for businesses. In March 2011, TWA was awarded the call for project for the Investments for the Future Program (PIA – Programme Investissements d’Avenir). It receives State aid through the ANR (Agence Nationale de la Recherche - National Research Agency). TWB is a UMS (Unité Mixte de Service – Mixed Service Unit) managed by INRA under triple INRA/INSA/CNRS tutelage. With €18 million in contracts signed at the end of 2015 after three years of full-time work, the relevance of TWB’s positioning and its role as an interface in public/private transfers have been reinforced.
More about TWB: www.toulouse-white-biotechnology.com
More about MetaToul: www.metatoul.fr

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company’s primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.
Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs 50 people in its offices and laboratories located in Montpellier, France.
More information at www.deinove.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160509006164/en/